PowerShow.com
  • Help
  • Preferences
  • Sign up
  • Log in
Advanced
Free template

Gurbel PowerPoint PPT Presentations

Grid List
All Time
All TimeAdded TodayAdded This WeekAdded This Month
Show:
Recommended
RecommendedRelevanceLatestHighest RatedMost Viewed
Sort by:
Featured Presentations
Search Results
Gurbel PA and Tantry US (2006) Drug Insight: clopidogrel nonresponsiveness PowerPoint PPT Presentation
Gurbel PA and Tantry US (2006) Drug Insight: clopidogrel nonresponsiveness - Title: PowerPoint Presentation Author. Last modified by: sudhindra Created Date: 10/13/2004 3:37:01 PM Document presentation format: On-screen Show
Title: PowerPoint Presentation Author. Last modified by: sudhindra Created Date: 10/13/2004 3:37:01 PM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to download
Gurbel PA1, Bliden K1, Storey RF2, Wei C3, Armstrong M3, Butler K3, Tantry US1 1Sinai Center for Thrombosis Research, Baltimore, Maryland, USA PowerPoint PPT Presentation
Gurbel PA1, Bliden K1, Storey RF2, Wei C3, Armstrong M3, Butler K3, Tantry US1 1Sinai Center for Thrombosis Research, Baltimore, Maryland, USA - First Analysis of Relation Between CYP2C19 Genotype and Platelet Function in Ticagrelor Versus Clopidogrel Treated Patients::: Results from the ONSET/OFFSET and ...
First Analysis of Relation Between CYP2C19 Genotype and Platelet Function in Ticagrelor Versus Clopidogrel Treated Patients::: Results from the ONSET/OFFSET and ...
| PowerPoint PPT presentation | free to download
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients  Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, PowerPoint PPT Presentation
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, - Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore
| PowerPoint PPT presentation | free to download
TRIP: Thrombotic Risk Progression  Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, MD PowerPoint PPT Presentation
TRIP: Thrombotic Risk Progression Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital of Baltimore Associate Professor of Medicine Johns Hopkins University School of Medicine Baltimore, MD - Title: Slide 1 Author: Phillip McCann Last modified by: Phillip McCann Created Date: 3/25/2007 2:13:54 PM Document presentation format: On-screen Show
Title: Slide 1 Author: Phillip McCann Last modified by: Phillip McCann Created Date: 3/25/2007 2:13:54 PM Document presentation format: On-screen Show
| PowerPoint PPT presentation | free to download
Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients with Stable Coronary Artery Disease: PowerPoint PPT Presentation
Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients with Stable Coronary Artery Disease: - Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, ... Paul A Gurbel, Kevin P Bliden, Udaya S Tantry, Tania Gesheff, Mark J Antonino ...
Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, ... Paul A Gurbel, Kevin P Bliden, Udaya S Tantry, Tania Gesheff, Mark J Antonino ...
| PowerPoint PPT presentation | free to download
CLEAR%20PLATELETS PowerPoint PPT Presentation
CLEAR%20PLATELETS - Title: Diapositive 1 Author: Elodie Last modified by: Herv Created Date: 7/26/2002 8:59:02 AM Document presentation format: Affichage l' cran (4:3)
Title: Diapositive 1 Author: Elodie Last modified by: Herv Created Date: 7/26/2002 8:59:02 AM Document presentation format: Affichage l' cran (4:3)
| PowerPoint PPT presentation | free to download
Bivalirudin With and Without Eptifibatide for Elective Stenting:  A Pharmacodynamic Study of Platelet Reactivity in Relation to the Occurrence of Periprocedural Myocardial Infarction  (The CLEAR PLATELETS-2 Study) PowerPoint PPT Presentation
Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation to the Occurrence of Periprocedural Myocardial Infarction (The CLEAR PLATELETS-2 Study) - Title: Slide 1 Author: kevin Last modified by: LifeBridge Health Created Date: 5/4/2004 9:10:57 PM Document presentation format: On-screen Show Company
Title: Slide 1 Author: kevin Last modified by: LifeBridge Health Created Date: 5/4/2004 9:10:57 PM Document presentation format: On-screen Show Company
| PowerPoint PPT presentation | free to download
Diapositiva 1 PowerPoint PPT Presentation
Diapositiva 1 - Title: Diapositiva 1 Author: cardiologia Last modified by: Tekno Created Date: 9/17/2011 11:25:31 AM Document presentation format: Presentazione su schermo (4:3)
Title: Diapositiva 1 Author: cardiologia Last modified by: Tekno Created Date: 9/17/2011 11:25:31 AM Document presentation format: Presentazione su schermo (4:3)
| PowerPoint PPT presentation | free to download
TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS PowerPoint PPT Presentation
TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS - tailored clopidogrel loading dose according to platelet reactivity monitoring decrease early stent thrombosis l bonello, l camoin-jau, s arques, , p .
tailored clopidogrel loading dose according to platelet reactivity monitoring decrease early stent thrombosis l bonello, l camoin-jau, s arques, , p .
| PowerPoint PPT presentation | free to download
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease PowerPoint PPT Presentation
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease - Title: Slide 1 Author: jcorner Created Date: 9/11/2008 12:20:21 PM Document presentation format: On-screen Show (4:3) Company: Mudskipper Other titles
Title: Slide 1 Author: jcorner Created Date: 9/11/2008 12:20:21 PM Document presentation format: On-screen Show (4:3) Company: Mudskipper Other titles
| PowerPoint PPT presentation | free to download
Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients with Stable Coronary Artery Disease: PowerPoint PPT Presentation
Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients with Stable Coronary Artery Disease: - Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients with Stable Coronary Artery Disease:
Randomized Double-Blind Assessment of the ONSET and OFFSet of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients with Stable Coronary Artery Disease:
| PowerPoint PPT presentation | free to download
Sunil V Rao MD Assistant Professor of Medicine Duke University Medical Center The Duke Clinical Rese PowerPoint PPT Presentation
Sunil V Rao MD Assistant Professor of Medicine Duke University Medical Center The Duke Clinical Rese - 'Non-responsiveness' defined as ? platelet aggregation 10% (baseline post procedure) ... ARMYDA-2: Periprocedural marker release. Patti G, et al. Circulation 2005 ...
'Non-responsiveness' defined as ? platelet aggregation 10% (baseline post procedure) ... ARMYDA-2: Periprocedural marker release. Patti G, et al. Circulation 2005 ...
| PowerPoint PPT presentation | free to view
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response: A Multicentre Randomized Prospective Study. PowerPoint PPT Presentation
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response: A Multicentre Randomized Prospective Study. - Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response:
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response:
| PowerPoint PPT presentation | free to view
TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS PowerPoint PPT Presentation
TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS - L Bonello, L Camoin-Jau, S Arques, , P . Rossi, C. Boyer, D Panagides, O Wittenberg, P Barragan, ... Service de cardiologie, Clinique clairval, Marseille; FRANCE ...
L Bonello, L Camoin-Jau, S Arques, , P . Rossi, C. Boyer, D Panagides, O Wittenberg, P Barragan, ... Service de cardiologie, Clinique clairval, Marseille; FRANCE ...
| PowerPoint PPT presentation | free to download
Bivalirudin With and Without Eptifibatide for Elective Stenting:  A Pharmacodynamic Study of Platelet Reactivity in Relation to the Occurrence of Periprocedural Myocardial Infarction  (The CLEAR PLATELETS-2 Study) PowerPoint PPT Presentation
Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation to the Occurrence of Periprocedural Myocardial Infarction (The CLEAR PLATELETS-2 Study) - A Pharmacodynamic Study of Platelet Reactivity in Relation to ... University of Oklahoma Health Sciences Center - J Saucedo. Exclusion Criteria: Blood Samples: ...
A Pharmacodynamic Study of Platelet Reactivity in Relation to ... University of Oklahoma Health Sciences Center - J Saucedo. Exclusion Criteria: Blood Samples: ...
| PowerPoint PPT presentation | free to download
Ask The Experts PowerPoint PPT Presentation
Ask The Experts - ... In Vitro Antiplatelet Effects of Active Metabolites in PRP ... their loading dose after ... that did not achieve statistical significance ...
... In Vitro Antiplatelet Effects of Active Metabolites in PRP ... their loading dose after ... that did not achieve statistical significance ...
| PowerPoint PPT presentation | free to download
Dominick J. Angiolillo, MD, PhD, FACC, FESC PowerPoint PPT Presentation
Dominick J. Angiolillo, MD, PhD, FACC, FESC - 7800 Patients with successful implantation of DES at 50 sites in US and Canada ... WHAT do we do with the results coming from the 'test tube' ...
7800 Patients with successful implantation of DES at 50 sites in US and Canada ... WHAT do we do with the results coming from the 'test tube' ...
| PowerPoint PPT presentation | free to download
Ask The Experts PowerPoint PPT Presentation
Ask The Experts - Welcome Ask The Experts March 24-27, 2007 New Orleans, LA Christopher P. Cannon, MD Senior Investigator, TIMI Study Group Cardiovascular Division Brigham and Women's ...
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA Christopher P. Cannon, MD Senior Investigator, TIMI Study Group Cardiovascular Division Brigham and Women's ...
| PowerPoint PPT presentation | free to download
Should%20we%20Monitor%20Anti-Platelet%20Treatment? PowerPoint PPT Presentation
Should%20we%20Monitor%20Anti-Platelet%20Treatment? - Is there a reliable test to measure platelet function? ... Poor response to clopidogrel was prospectively defined by a cutoff point at the ...
Is there a reliable test to measure platelet function? ... Poor response to clopidogrel was prospectively defined by a cutoff point at the ...
| PowerPoint PPT presentation | free to download
Pr PowerPoint PPT Presentation
Pr - Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2* loss-of function polymorphism.
Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19 2* loss-of function polymorphism.
| PowerPoint PPT presentation | free to download
TEG PowerPoint PPT Presentation
TEG - teg teg ? teg
teg teg ? teg
| PowerPoint PPT presentation | free to download
A CME-CERTIFIED GRAND ROUNDS PROGRAM PowerPoint PPT Presentation
A CME-CERTIFIED GRAND ROUNDS PROGRAM - Prasugrel 60 mg should be given as soon as possible for primary PCI. MODIFIED Recommendation. Anderson JL et al. Circulation. 2007;116:803-877. O Connor JE et al.
Prasugrel 60 mg should be given as soon as possible for primary PCI. MODIFIED Recommendation. Anderson JL et al. Circulation. 2007;116:803-877. O Connor JE et al.
| PowerPoint PPT presentation | free to view
Platelet Function Testing PowerPoint PPT Presentation
Platelet Function Testing - Platelet Function Testing John Francis Ph.D. Florida Hospital Center for Hemostasis and Thrombosis, Orlando, FL, USA www.fhitr.com Typical approach to platelet ...
Platelet Function Testing John Francis Ph.D. Florida Hospital Center for Hemostasis and Thrombosis, Orlando, FL, USA www.fhitr.com Typical approach to platelet ...
| PowerPoint PPT presentation | free to download
NSTEMI PowerPoint PPT Presentation
NSTEMI - Title: Slide 1 Author: Annie Bedard Last modified by: craig Created Date: 4/18/2013 1:36:54 PM Document presentation format: On-screen Show (4:3) Company
Title: Slide 1 Author: Annie Bedard Last modified by: craig Created Date: 4/18/2013 1:36:54 PM Document presentation format: On-screen Show (4:3) Company
| PowerPoint PPT presentation | free to view
Pooled analysis from 4 ISAR trials: Multivariate predictors of major bleeding PowerPoint PPT Presentation
Pooled analysis from 4 ISAR trials: Multivariate predictors of major bleeding - Triple therapy length: 5.6 4.6 mo (DES 7.7 3.6 vs BMS 3.1 3.6, P 0.001) ... Significant difference between gps A vs C and B vs C, but not A vs B were found ...
Triple therapy length: 5.6 4.6 mo (DES 7.7 3.6 vs BMS 3.1 3.6, P 0.001) ... Significant difference between gps A vs C and B vs C, but not A vs B were found ...
| PowerPoint PPT presentation | free to view
Stephen D' Wiviott, MD Cardiovascular Division Brigham and Womens Hospital Assistant Professor of Me PowerPoint PPT Presentation
Stephen D' Wiviott, MD Cardiovascular Division Brigham and Womens Hospital Assistant Professor of Me - Limitations of Current Antiplatelet Therapy in ACS and PCI ... Irreversibility and bleeding (especially related to CABG) Modest levels of platelet inhibition ...
Limitations of Current Antiplatelet Therapy in ACS and PCI ... Irreversibility and bleeding (especially related to CABG) Modest levels of platelet inhibition ...
| PowerPoint PPT presentation | free to download
Manejo del Angor Inestable e Infarto Agudo en la Sala de Hemodinamia PowerPoint PPT Presentation
Manejo del Angor Inestable e Infarto Agudo en la Sala de Hemodinamia - No hay conflicto de inter s que declarar. Curso Trianual de Cardiolog a ... son recomendaciones, lo que puede o deber a hacer y no lo que se debe hacer. ...
No hay conflicto de inter s que declarar. Curso Trianual de Cardiolog a ... son recomendaciones, lo que puede o deber a hacer y no lo que se debe hacer. ...
| PowerPoint PPT presentation | free to download
A PowerPoint PPT Presentation
A - Title: Presentaci n de PowerPoint Author: Congregacion Mariana Last modified by: aalmonacid Created Date: 11/18/2003 5:38:14 PM Document presentation format
Title: Presentaci n de PowerPoint Author: Congregacion Mariana Last modified by: aalmonacid Created Date: 11/18/2003 5:38:14 PM Document presentation format
| PowerPoint PPT presentation | free to download
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Reduce Early Stent PowerPoint PPT Presentation
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Reduce Early Stent - Service de cardiologie, H pital Universitaire Nord, Marseille; FRANCE. Presented at AHA 2008 ... Large inter-individual variability in response to clopidogrel ...
Service de cardiologie, H pital Universitaire Nord, Marseille; FRANCE. Presented at AHA 2008 ... Large inter-individual variability in response to clopidogrel ...
| PowerPoint PPT presentation | free to download
Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study PowerPoint PPT Presentation
Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study - Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study
Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study
| PowerPoint PPT presentation | free to download
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. PowerPoint PPT Presentation
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. - These data form the GRACE registry show that there is an association between bleeding and morality ... Time Admission Cath Discharge No Cath Cath PCI Surgery ...
These data form the GRACE registry show that there is an association between bleeding and morality ... Time Admission Cath Discharge No Cath Cath PCI Surgery ...
| PowerPoint PPT presentation | free to download
Primary Results of The Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety Trial PowerPoint PPT Presentation
Primary Results of The Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety Trial - Primary Results of The Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety Trial GRAVITAS AHA 2010 Matthew J. Price, MD
Primary Results of The Gauging Responsiveness with A VerifyNow Assay - Impact on Thrombosis And Safety Trial GRAVITAS AHA 2010 Matthew J. Price, MD
| PowerPoint PPT presentation | free to download
What PowerPoint PPT Presentation
What - What s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre
What s New in Acute Coronary Syndromes? Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre
| PowerPoint PPT presentation | free to download
Ask The Experts PowerPoint PPT Presentation
Ask The Experts - Welcome Ask The Experts March 24-27, 2007 New Orleans, LA AntiPlatelet Therapy in ACS and PCI Stephen D. Wiviott, MD Associate Physician, Cardiovascular Division ...
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA AntiPlatelet Therapy in ACS and PCI Stephen D. Wiviott, MD Associate Physician, Cardiovascular Division ...
| PowerPoint PPT presentation | free to download
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. PowerPoint PPT Presentation
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. - Accreditation Information Program Requirements Accreditation Information Accreditation Information ACS Forum Leadership Panel ACS Forum Leadership Panel ACS Forum ...
Accreditation Information Program Requirements Accreditation Information Accreditation Information ACS Forum Leadership Panel ACS Forum Leadership Panel ACS Forum ...
| PowerPoint PPT presentation | free to download
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease PowerPoint PPT Presentation
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease - Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease ... PCI = percutaneous coronary intervention; PVD = peripheral vascular disease ...
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease ... PCI = percutaneous coronary intervention; PVD = peripheral vascular disease ...
| PowerPoint PPT presentation | free to view
Eric R. Bates, MD PowerPoint PPT Presentation
Eric R. Bates, MD - LTA = light transmission aggregometry; PFA = platelet function ... St. John's wort. 300 mg tid. P=0.004. P=0.004. P=0.03. Resistant Platelets: What Can Be Done? ...
LTA = light transmission aggregometry; PFA = platelet function ... St. John's wort. 300 mg tid. P=0.004. P=0.004. P=0.03. Resistant Platelets: What Can Be Done? ...
| PowerPoint PPT presentation | free to view
A PowerPoint PPT Presentation
A - Title: Presentaci n de PowerPoint Author: Congregacion Mariana Last modified by: aalmonacid Created Date: 11/18/2003 5:38:14 PM Document presentation format
Title: Presentaci n de PowerPoint Author: Congregacion Mariana Last modified by: aalmonacid Created Date: 11/18/2003 5:38:14 PM Document presentation format
| PowerPoint PPT presentation | free to download
ADAPT-DES Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents A Large-Scale, Prospective, Multicenter Registry Examining the Relationship Between Platelet Responsiveness and Stent Thrombosis              After DES Implantation PowerPoint PPT Presentation
ADAPT-DES Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents A Large-Scale, Prospective, Multicenter Registry Examining the Relationship Between Platelet Responsiveness and Stent Thrombosis After DES Implantation - ADAPT-DES: Study organization Principal investigator: ... VerifyNow P2Y12 % Highest 4 Quintiles (11) (n=6745) P
ADAPT-DES: Study organization Principal investigator: ... VerifyNow P2Y12 % Highest 4 Quintiles (11) (n=6745) P
| PowerPoint PPT presentation | free to download
Antiagregantes plaquetarios en el paciente quirъrgico: Actualizaciуn PowerPoint PPT Presentation
Antiagregantes plaquetarios en el paciente quirъrgico: Actualizaciуn - Antiagregantes plaquetarios en el paciente quir rgico: Actualizaci n Purificaci n Matute Carmen Gomar Reinicio antiagregaci n Lo antes posible (tarde) AAS ...
Antiagregantes plaquetarios en el paciente quir rgico: Actualizaci n Purificaci n Matute Carmen Gomar Reinicio antiagregaci n Lo antes posible (tarde) AAS ...
| PowerPoint PPT presentation | free to download
Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? PowerPoint PPT Presentation
Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current Antiplatelet Therapy Adequate? - Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current ...
Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention: Is the Current ...
| PowerPoint PPT presentation | free to download
Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study PowerPoint PPT Presentation
Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study - Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study
Assessment of Cardiopulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor or Clopidogrel in the ONSET/OFFSET Study
| PowerPoint PPT presentation | free to download
Emerging Therapeutic Approaches to Reduce the Incidence of PCIRelated ACS PowerPoint PPT Presentation
Emerging Therapeutic Approaches to Reduce the Incidence of PCIRelated ACS - 49 yo F with a h/o HTN, HL, strong FH of CAD admitted with new onset CP ... Denied SOB, N/V, lightheadedness or diaphoresis. Courtesy of M O'Donoghue (BWH/MGH) ...
49 yo F with a h/o HTN, HL, strong FH of CAD admitted with new onset CP ... Denied SOB, N/V, lightheadedness or diaphoresis. Courtesy of M O'Donoghue (BWH/MGH) ...
| PowerPoint PPT presentation | free to view
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education a PowerPoint PPT Presentation
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education a - American Heart Association, Atlanta. Division. Atlanta, GA. Ralph G. Nader, MD, FACC, FACP, FSCAI ... Consulting/Honoraria: Bristol Myers-Squibb, Eisai ...
American Heart Association, Atlanta. Division. Atlanta, GA. Ralph G. Nader, MD, FACC, FACP, FSCAI ... Consulting/Honoraria: Bristol Myers-Squibb, Eisai ...
| PowerPoint PPT presentation | free to download
How will we Treat Acute Coronary Syndrome Patients in the Future PowerPoint PPT Presentation
How will we Treat Acute Coronary Syndrome Patients in the Future - Pro-drug. Hepatic metabolism. Cytochrome P450. Active metabolite. N. S. O ... ClinicalTrials.gov Identifier: NCT00391872. Cangrelor. Intravenous P2Y12 Inhibitor ...
Pro-drug. Hepatic metabolism. Cytochrome P450. Active metabolite. N. S. O ... ClinicalTrials.gov Identifier: NCT00391872. Cangrelor. Intravenous P2Y12 Inhibitor ...
| PowerPoint PPT presentation | free to view
Antiplatelet Drug Resistance in Coronary Artery Disease: PowerPoint PPT Presentation
Antiplatelet Drug Resistance in Coronary Artery Disease: - Director of Cardiovascular Research. Assistant Professor of Medicine ... (PRI 50%) received additional 600mg bolus (max 2400 mg) until reaching therapeutic target. ...
Director of Cardiovascular Research. Assistant Professor of Medicine ... (PRI 50%) received additional 600mg bolus (max 2400 mg) until reaching therapeutic target. ...
| PowerPoint PPT presentation | free to view
Clopidogrel (Plavix) By Oksana Ekkert PowerPoint PPT Presentation
Clopidogrel (Plavix) By Oksana Ekkert - Clopidogrel (Plavix) By Oksana Ekkert Not only CYP2C19 genetics, but-- Genetics of CYP2C9*3 and ABCB1 have been shown to be important Not only CYP2C19 genetics, but ...
Clopidogrel (Plavix) By Oksana Ekkert Not only CYP2C19 genetics, but-- Genetics of CYP2C9*3 and ABCB1 have been shown to be important Not only CYP2C19 genetics, but ...
| PowerPoint PPT presentation | free to view
CHAMPION PLATFORM PowerPoint PPT Presentation
CHAMPION PLATFORM - Deepak L. Bhatt, MD, MPH, A. Michael Lincoff, MD, C. Michael Gibson, MS, MD, Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD,
Deepak L. Bhatt, MD, MPH, A. Michael Lincoff, MD, C. Michael Gibson, MS, MD, Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD,
| PowerPoint PPT presentation | free to download
Antiplatelet Interventions in Acute Coronary Syndromes PowerPoint PPT Presentation
Antiplatelet Interventions in Acute Coronary Syndromes - Thrombus Susceptibility and the Vulnerable Plaque: ... OPUS-TIMI 16. Sabatine MS et al. Circulation. 2002;105:1760-3. TACTICS-TIMI 18. 1. 1.8 ...
Thrombus Susceptibility and the Vulnerable Plaque: ... OPUS-TIMI 16. Sabatine MS et al. Circulation. 2002;105:1760-3. TACTICS-TIMI 18. 1. 1.8 ...
| PowerPoint PPT presentation | free to view
Ranolazine in Patients with Incomplete Revascularization After Percutaneous Coronary Intervention PowerPoint PPT Presentation
Ranolazine in Patients with Incomplete Revascularization After Percutaneous Coronary Intervention - Vasilieva Elena, City Clinical Hospital # 23 n.a. Medsantrud , Moscow.Spain (total enrolment = 174): Moris Cesar, Hospital Central de Asturias, Oviedo.
Vasilieva Elena, City Clinical Hospital # 23 n.a. Medsantrud , Moscow.Spain (total enrolment = 174): Moris Cesar, Hospital Central de Asturias, Oviedo.
| PowerPoint PPT presentation | free to download
UPDATE%20ON%20ANTIPLATELET%20THERAPY%20IN%20THE%20TREATMENT%20AND%20PREVENTION%20OF%20CARDIOVASCULAR%20DISEASE PowerPoint PPT Presentation
UPDATE%20ON%20ANTIPLATELET%20THERAPY%20IN%20THE%20TREATMENT%20AND%20PREVENTION%20OF%20CARDIOVASCULAR%20DISEASE - ... placebo-controlled trials show that both PPIs and histamine-2 receptor antagonists decrease the development of endoscopic ulcers in low-dose aspirin ... CABG ...
... placebo-controlled trials show that both PPIs and histamine-2 receptor antagonists decrease the development of endoscopic ulcers in low-dose aspirin ... CABG ...
| PowerPoint PPT presentation | free to download
Antiplatelet drug resistance: Definitions, diagnosis, and implications for personalized medicine PowerPoint PPT Presentation
Antiplatelet drug resistance: Definitions, diagnosis, and implications for personalized medicine - Antiplatelet drug resistance: Definitions, diagnosis, and implications for personalized medicine Peter Berger, MD Interventional Cardiologist Director, Center for ...
Antiplatelet drug resistance: Definitions, diagnosis, and implications for personalized medicine Peter Berger, MD Interventional Cardiologist Director, Center for ...
| PowerPoint PPT presentation | free to view
Point of Care Platelet Function Testing  PowerPoint PPT Presentation
Point of Care Platelet Function Testing - Aggregation based, platelet rich plasma (PRP) ADP peak platelet aggregation. Central laboratory, trained technicians . ... Compared with standard-dose therapy, ...
Aggregation based, platelet rich plasma (PRP) ADP peak platelet aggregation. Central laboratory, trained technicians . ... Compared with standard-dose therapy, ...
| PowerPoint PPT presentation | free to view
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. PowerPoint PPT Presentation
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education and CMEducation Resources, LLC. - Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education a
Jointly Sponsored by the University of Massachusetts Medical School Office of Continuing Education a
| PowerPoint PPT presentation | free to download
Clinical Insights, Risk Stratification, and Enhancing Outcomes PowerPoint PPT Presentation
Clinical Insights, Risk Stratification, and Enhancing Outcomes - 2005:294:3108-16. Clinical implications ... ISAR-SWEET: Study design. Aspirin 500 mg and heparin ... ISAR-SWEET: Neutral effect. on primary outcome in diabetes ...
2005:294:3108-16. Clinical implications ... ISAR-SWEET: Study design. Aspirin 500 mg and heparin ... ISAR-SWEET: Neutral effect. on primary outcome in diabetes ...
| PowerPoint PPT presentation | free to view
CHAMPION PLATFORM PowerPoint PPT Presentation
CHAMPION PLATFORM - Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD, ... Khan. Tomball Regional Hospital. 56. USA. Ferrier. Rapid City Regional Hospital. 50. India ...
Gregg W. Stone, MD, Steven McNulty, MS, Gilles Montalescot, MD, PhD, ... Khan. Tomball Regional Hospital. 56. USA. Ferrier. Rapid City Regional Hospital. 50. India ...
| PowerPoint PPT presentation | free to download
Page of  


PowerPlugs
PowerPlugs
View by Category
Presentations
  • Photo Slideshows
  • Presentations (free-to-view)
    • Concepts & Trends
    • Entertainment
    • Fashion & Beauty
    • Government & Politics
    • How To, Education & Training
    • Medicine, Science & Technology
    • Other
    • Pets & Animals
    • Products & Services
    • Religious & Philosophical
    • Travel & Places
  • Presentations (pay-to-view)
Products Sold on our sister site CrystalGraphics.com
  • Ultimate Combo for PPT
  • PowerPoint Templates
  • Charts & Diagrams for PPT
  • 3D Character Slides
  • Background Videos for PPT
  • More Products for PPT
PowerPlugs
PowerPlugs
CrystalGraphics
Home About Us Terms and Conditions Privacy Policy Contact Us Send Us Feedback
Copyright 2021 CrystalGraphics, Inc. — All rights Reserved. PowerShow.com is a trademark of CrystalGraphics, Inc.
gurbel — Search results on PowerShow.com
Loading...